ArticleDermatologie (Heidelberg, Germany)2026
[When the etiology remains unclear: status quo of chronic pruritus of unknown origin].
Article in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pruritus of unknown origin (CPUO) is diagnosed when no underlying cause for the itching can be identified. Although the exact pathophysiology remains largely unclear, neuroimmune mechanisms are believed to play an important role. Clinically, CPUO typically begins on normal appearing skin, but secondary scratch excoriations may develop over time. Itching is usually moderate to severe, occurs daily, and is associated with substantial disease burden and impairment of quality of life. Since CPUO is a diagnosis of exclusion, a comprehensive diagnostic evaluation is necessary to rule out potential causes of chronic itching. This includes a comprehensive general and itch-specific medical history, a complete dermatological examination, a core laboratory workup, and individually tailored complementary diagnostic procedures. Currently, there is no approved treatment for CPUO. According to German directives, antihistamines can be prescribed for severe, persistent itching; however, their effectiveness is limited. The German guideline recommends the use of antihistamines and gabapentinoids as first-line therapies, while paroxetine, mirtazapine, phototherapy, and opioid receptor modulators constitute alternative 2nd to 5th line options. Biologics, particularly dupilumab and nemolizumab, are currently being investigated in clinical trials and may expand the therapeutic options for this indication in the future.
Indexed as
Identifiers
42201368What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.